MFN affecting Swiss medicines access, says Interpharma
Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.
Newsletters and Deep Dive digital magazine
Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.
ICER says that AstraZeneca's first-in-class Baxfendy and a rival drug from Mineralys are not cost-effective as therapies for resistant hypertension.
Three pharma groups have opened a new front in their legal challenge to the federal 340B drug pricing programme in the US.
ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.
Trump has signed an order that rips up the current US policy on childhood vaccines, demanding changes that experts say will put children at risk.
Editor's Picks
Newsletters and Deep Dive
digital magazine